The Pricing Evolution of Personalized Medicines

Grant D. Lawless, RPh, MD, FACP

Video Categories: Pricing

Grant Lawless discusses the changing landscape of pricing personalized medicines
November 19, 2014

Optimal Value-Based Therapy

Listen as Ken Schaecher, MD discusses the optimal value-based therapy for treatment of polycythemia vera.Supported through funding from Incyte

September 2, 2015

Aspirations for the Launch of Ixazomib

Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.